Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin

Abstract

The ability of adenovirus (Ad) to transfect most cell types efficiently1–3 has already resulted in human gene therapy trials involving the systemic administration of adenoviral constructs4. However, because of the complexity of brain function and the difficulty in noninvasively monitoring alterations in neuronal gene expression, the potential of Ad gene therapy strategies for treating disorders of the CNS has been difficult to assess. In the present study, we have used an Ad encoding the arginine vasopressin cDNA (AdAVP)5 in an AVP-deficient animal model of diabetes insipidus (the Brattleboro rat6), which allowed us to monitor chronically the success of the gene therapy treatment by noninvasive assays. Injection of AdAVP into the supraoptic nuclei (SON) of the hypothalamus resulted in expression of AVP in magnocellular neurons. This was accompanied by reduced daily water intake and urine volume, as well as increased urine osmolality lasting 4 months. These data show that a single gene defect leading to a neurological disorder can be corrected with an adenovirus-based strategy. This study highlights the potential of using Ad gene therapy for the long-term treatment of disorders of the CNS.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Cheng, D.Y., Kolls, J.K., Lei, D.H. & Noel, R.A. In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Hum. Gene Ther. 8, 755–764 (1997).

  2. 2

    Neve, R.L. Adenoviral vectors enter the brain. Trends Neurosci. 16, 251–253 (1993).

  3. 3

    Geddes, B.J. et al. Persistent transgene expression in the hypothatamus following stereotaxic delivery of a recombinant adenovirus- suppression of the immune response with cyclosporine. Endocrinology 137, 5166–5169 (1996).

  4. 4

    Wagner, J.A. & Gardner, P. Toward cystic fibrosis gene therapy. Anna. Rev. Med. 48, 203–216 (1997).

  5. 5

    Foo, N-C., Funkhouser, J.M., Carter, D.A. & Murphy, D. A testis-specific promoter in the rat vasopressin gene. J. Biol. Chem. 269, 659–667 (1994).

  6. 6

    Valtin, H. Hereditary diabetes insipidus in rats (Brattleboro strain). Am. J. Med. 42, 814–827 (1967).

  7. 7

    Gainer, H. & Wray, S. Cellular and molecular biology of oxytocin and vasopressin. in The Physiology of Reproduction, 2nd edn. (eds. E. Knobil & Neill) 4545–472 (Raven, New York, 1994).

  8. 8

    Burbach, J.P.H. et al. Differential responses to osmotic stress of vasopressin mRNA in hypothalamic nuclei. Neuroendocrinology 39, 582–584 (1984).

  9. 9

    Sherman, T.G., Civelli, O., Douglas, J., Herbert, E. & Watson, S.J. Coordinate expression of hypothalamic pro-dynorphin and pro-vasopressin mRNAs with osmotic stimulation. Neuroendocrinology 44, 222–228 (1986).

  10. 10

    Schmale, H. & Richter, D. Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 308, 705–709 (1984).

  11. 11

    Ivell, R., Burback, P.H. & Van Leeuwen, F.W. The molecular biology of the Brattleboro rat. Front. Neuroendocrinol. 4, 313–338 (1990).

  12. 12

    Repaske, D.R. & Phillips, J.A. The molecular biology of human hereditary diabetes insipidus. Prog. Brain Res. 93, 295–308 (1992).

  13. 13

    Jirikowski, G.F., Sanna, P.P., Maciejewski-Lenoir, D. & Bloom, F.E. Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA. Science 255, 996–998 (1992).

  14. 14

    Ben-Barak, Y., Russell, J.T., Whitnall, M.H., Ozato, K. & Gainer, H. Neurophysin in the hypothalamo-neurohypophysial system. I. Production and characterization of monoclonal antibodies. J. Neurosci. 5, 81–97 (1985).

  15. 15

    van Leeuwen, F.W., Evans, D.A.P., Meloen, R. & Sonnemans, M.A.F. Differential neurophysin immunoreactivities in solitary magnocellular neurons of the homozygous Brattleboro rat indicate an altered neurophysin moiety. Brain Res. 635, 328–330 (1994).

  16. 16

    Whitnall, M.H., Key, S., Ben-Barak, Y., Ozato, K. & Gainer, H. Neurophysin in the hypothalamo-neurohypophysial system. II. immunocytochemical studies of the ontogeny of oxytocinergic and vasopressinergic neurones. J. Neurosci. 5, 98–109 (1985).

  17. 17

    Pow, D.V., Morris, J.F. & Ward, A.R. Immuno-electron microscopic evidence for two different types of partial somatic repair of the mutant Brattleboro vasopressin gene. Neuroscience 50, 503–512 (1992).

  18. 18

    Graham, F.L. & Prevec, L. Methods for construction of adenovirus vectors. Mol. Biotech. 3, 207–220 (1995).

  19. 19

    Sofroniew, M.V. (1985) Vasopressin, oxytocin and their related neurophysins. in Handbook of Chemical Neuroanatomy. Vol. 4: GABA and neuropeptides in the CNS, Part 1 (eds. Bjorklund, A. & Hokfelt, T.) 35–44 (Elsevier, London, 1985).

  20. 20

    Harbuz, M.S. & Lightman, S.L. Response of hypothalamic and pituitary mRNA to physical and psychological stress in the rat. J. Endo. (Lond.) 122, 705–711 (1989).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Geddes, B., Harding, T., Lightman, S. et al. Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nat Med 3, 1402–1404 (1997). https://doi.org/10.1038/nm1297-1402

Download citation

Further reading